Corbus Pharmaceuticals Holdings Inc at Jefferies Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Yeah, that's a great intro. And you mentioned the deal with CSPC for CRB-701. Can you talk about how the deal came about? What the deal terms are? And how you currently work together with CSPC on the development of 701? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 07, 2023 / 7:00PM, CRBP.OQ - Corbus Pharmaceuticals Holdings Inc at Jefferies Healthcare Conference

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. That makes sense. And the important aspect of 701 is differentiation from PADCEV. Can you walk us through the data you have seen that convince you 701 is differentiated and potentially better than PADCEV? And maybe you can start from the structural differences, and also talk about why the different design could lead to a better profile, particularly with toxicity?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got them. And can you talk a little bit more about some of the specifics with 701, including the linker, also whether it's chemical based, and also the DAR as well? And how that compares to PADCEV?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got them. And as one of the questions I add to just on CMC. Do you anticipate any challenges related to CMC? And longer term, will see CSPC be the commercial supplier or do you have a contract in it?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got them. And you talked about how 701 would allow a better dosing schedule than PADCEV, which is once weekly. How does 701 allow for a better dosing? And does it mean you give a higher dose per injection? Could there be potentially additional safety risks that arise from that? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 07, 2023 / 7:00PM, CRBP.OQ - Corbus Pharmaceuticals Holdings Inc at Jefferies Healthcare Conference

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got them. And for the study in China that you mentioned for 701, you said six cohorts. They're in the middle there in cohort 3. Is there anything else about the design you want to highlight? And when could you get an initial update from that study? And when could it formally readout as well?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got them. And for your bridging study, how many patients do you think you would need for that? And what kind of data are you going to be looking for in that study?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got them. And just to clarify, so for the CSPC study, their PADCEV-naive patients, could that make safety look artificially better or worse? And then would your study have to include PADCEV-naive patients?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Makes sense. And let's see. And you mentioned the 18.1 Claudin -- 18.2 data at ASCO of investor interest to compare it to other Claudin 18.2 ADCs, what are the data that could have read through to 701? And is there anything we can learn from the safety profile? Maybe talk a little bit more about that.

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. And what's the DAR for that compound? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. JUNE 07, 2023 / 7:00PM, CRBP.OQ - Corbus Pharmaceuticals Holdings Inc at Jefferies Healthcare Conference

Question: Maury Raycroft - Jefferies Group LLC - Analyst : The same? Okay. Okay. And let's see. For prep work for deciding which tumors you're going to pursue. Maybe talk a little bit more about that. And what's some of the considerations are there?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Okay. And Mabwell recently reported data on their Nectin-4 ADC. 50% overall response rate and 100% disease control. and six patients for cervical carcinoma, and 12 patients with urothelial carcinoma. They also published a paper with our preclinical data recently. What do you think of their data overall and how it compares to 701?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Right. Makes sense. And let's shift gears to 601. You mentioned it's a V beta 6 (sic - "a V beta 8") antibody that inhibits TGF beta. And you recently had a KOL call on this. What were some of the key takes from the call?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. And you also had some data at AACR as well for this program and the [NYA] meeting. You've showed some combo data too with checkpoint inhibitor. Maybe talk a little bit more about the strategy there?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Makes sense. And what's the longer-term timeline there? I guess, for 601, with getting into clinic --?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Okay. And for 1801, I think Elevation Oncology is running a bridging study as well. Could that study readout before -- I guess, could that be a near-term data update that helps provide some perspective into -- I don't it's near term. I think it's going to be maybe a year from now or so?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Okay. Well, in the last couple of seconds, if you just wanted to highlight key events ahead that investors should be focused on?

Question: Maury Raycroft - Jefferies Group LLC - Analyst : Got it. Great. Thanks to you all. Thanks for joining us.